Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Participants who are diagnosed as Lennox-Gastaut syndrome with tonic/atonic seizures and atypical absence seizures (A history of atypical absence seizures will also be incorporated).~2. Participants who had a slow spike-and-wave pattern in an electroencephalogram within 6 months prior to the enrollment for the Observation Period.~3. Participants who had at least a total of 90 seizures in the 28 days prior to the enrollment for the Observation Period.~4. Participants who have been on 1 - 3 anti-epileptic drugs from 28 days prior to the enrollment for the Observation Period and have not changed the type of the anti-epileptic drugs.~5. Participants who have not changed the type nor the dose or administration of the anti-epileptic drugs they are taking in the Observation Period.~Exclusion criteria;~1. Participants who had a history of generalized tonic-clonic status epilepticus within baseline.~2. Participants who received drug therapy at least 4 times to be rescued from status epilepticus within baseline.~3. Participants who had a history of hypoxia which needed emergency resuscitation within 12 months prior to the Treatment Period.~4. Participants who were on a ketogenic diet or have received adrenocorticotropic hormone (ACTH) therapy or Vitamin B6 therapy within 6 months prior to the Treatment Period.~5. Participants who had a history of suicide attempt within the 1 year prior to the Treatment Period.~6. Participants who had a history of or has an allergy to triazole compound.~7. Participants who have clinically significant electrocardiogram abnormalities at baseline.~8. Participants who are pregnant, who may be pregnant, who are lactating or who wish to be pregnant.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Rufinamide (E2080) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).